89724-32-3

Upstream product

• 108192-92-3 (2-cyclohexyl-5-methyl-oxazol-4-yl)acetonitrile 
• 61152-00-9 2-cyclohexyl-5-methyl-oxazole-4-carboxylic acid ethyl ester 
• 61152-04-3 2-cyclohexyl-5-methyl-oxazole-4-carboxylic acid 
• 51655-86-8 2-cyclohexyl-5-methyl-oxazole-4-carbonyl chloride 
• 89744-48-9 (S)-2-(Cyclohexanecarbonyl-amino)-succinic acid 4-methyl ester 
• 107367-85-1 (S)-3-(Cyclohexanecarbonyl-amino)-4-oxo-pentanoic acid methyl ester 
• 136058-64-5 4-chloromethyl-2-cyclohexyl-5-methyl-oxazole 
• 89724-31-2 2-Cyclohexyl-4-hydroxymethyl-5-methyloxazole 
• 61151-95-9 2-cyclohexanecarbonylamino-3-oxo-butyric acid ethyl ester 
• 401791-01-3 3-(cyclohexanecarbonyl-amino)-4-oxo-pentanoic acid benzyl ester 
• 2719-27-9 cyclohexanylcarbonyl chloride 
• 401791-02-4 (2-cyclohexyl-5-methyl-oxazol-4-yl)-acetic acid benzyl ester 

Downstream Products

• 132646-47-0 2-(2-cyclohexyl-5-methyl-oxazol-4-yl)-ethanol 

Relevant academic research and scientific papers

SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS

The present invention relates to compounds of formula (I) wherein R1 to R8 and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Application of the Dakin-West reaction for the synthesis of oxazole-containing dual PPARα/γ agonists

An improved method for the preparation of a series of oxazole-containing dual PPARα/γ agonists is described. A synthetic sequence utilizing a Dakin-West reaction was devised that allows for the introduction of the oxazole ring either late in the synthetic sequence via aminomalonate-derived chemistry or in pivotal SAR intermediates derived from aspartic acid.

Oxazolidinedione hypoglycemic agents

Compounds of the formulae STR1 where R is cycloalkyl or aryl; R1 is alkyl, X is O or C=O; A is O or S; and B is N or CH are useful as hypoglycemic agents.

Oxazolidinedione hypoglycemic agents

Compounds of the formulae where R is cycloalkyl or aryl; R1 is alkyl, X is O or C=O; A is O or S; and B is N or CH are useful as hypoglycemic agents.

Oxazoleacetic acid derivatives

A compound of the formula: STR1 wherein R1 is (A) a group of the formula, STR2 wherein R4 is H, a halogen or trifluoromethyl group, or (B) a group of the formula, STR3 wherein n is 0 or an integer of 1 to 3; R5 is H or an